


**Product Name** : IMR-687  
**Cat. No.** : PC-72172  
**CAS No.** : 2062661-53-2  
**Molecular Formula** : C<sub>21</sub>H<sub>26</sub>N<sub>6</sub>O<sub>2</sub>  
**Molecular Weight** : 394.479  
**Target** : Phosphodiesterase (PDE)  
**Solubility** : 10 mM in DMSO



## Biological Activity

IMR-687 (IMR687, Tovinsontrine) is a novel, potent and selective phosphodiesterase-9 (**PDE-9**) inhibitor with IC<sub>50</sub> of 8.19 nM and 9.99 nM against PDE9A1 and PDE9A2, respectively.

IMR-687 (Tovinsontrine) displays >800-fold greater potency than PDE1A3, PDE1B, PDE1C, PDE5A2 (IC<sub>50</sub> values >8 μM).

IMR-687 (Tovinsontrine) recapitulates the cGMP and fetal hemoglobin (HbF) induction mechanism of hydroxyurea (HU) in erythroid cells.

Treatment of phosphodiesterase 9A inhibitor (IMR-687, Tovinsontrine) in sickle mice for 30 days results in fetal hemoglobin (HbF) induction, reduced hemolysis and reticulocytosis, as well as immune cell activity.

IMR-687 (Tovinsontrine) increases F-cells in patient-derived sickle cell disease (SCD) CD36+ cells, reduces vessel-occlusion in the Townes-HbSS sickle cell disease model.

## References

McArthur JG, et al. *Haematologica*. 2020 Mar;105(3):623-631.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com